Article
Reduced clinical efficacy of pazufloxacin against gonorrhea due to high prevalence of quinolone-resistant isolates with the GyrA mutation. The Pazufloxacin STD Group.
Antimicrobial agents and chemotherapy - 1 Mar 1998
Tanaka M, Matsumoto T, Sakumoto M, Takahashi K, Saika T, Kabayashi I, Kumazawa J
Abstract excerpt
Forty-two men with gonococcal urethritis were treated with an oral dosage of 200 mg of pazufloxacin, a new fluoroquinolone, three times daily for 3 days. Only 28 of the 42 men (66.7%) had negative culture results for Neisseria gonorrhoeae during follow-up. Of the 42 isolates, 41 could be recultur...
Topics
- Adult
- Anti-Infective Agents
- DNA Gyrase
- DNA Topoisomerase IV
- DNA Topoisomerases, Type II
- Drug Resistance, Microbial
- Fluoroquinolones
- Gonorrhea
- Humans
- Male
- Microbial Sensitivity Tests
- Middle Aged
- Mutation
- Neisseria gonorrhoeae
- Oxazines